Related Experiment Video
Updated: Mar 21, 2026
Biosensor-based High Throughput Biopanning and Bioinformatics Analysis Strategy for the Global Validation of Drug-protein Interactions
Published on: December 1, 2020
In silico design, drug-likeness evaluation, and binding recognition of Tanshinone I-based PARP1 inhibitors
Mwanahamis Peter Makolo1, Ismail Abubakari1, Marwa Emmanuel1
1Department of Chemistry, College of Natural and Mathematical Sciences, The University of Dodoma, United Republic of Tanzania, P.O.Box 338, Dodoma, Tanzania.
Abstract:
BRCA-driven cancers remain a challenge worldwide due to PARP1's critical role in DNA repair and cancer cell survival. Therefore, PARP1 is an important target for the treatment of BRCA-related cancers. However, current PARP1 inhibitors have toxicity and resistance issues, highlighting the need for new scaffolds. In search of compounds, Tanshinone I emerged as a promising candidate with known anticancer properties. However, its poor solubility and bioavailability, as well as its unknown interaction with PARP1, limit its clinical potential. In this study, Tanshinone I was modified to enhance its solubility and bioavailability by introducing carboxamide and pyrrolidine moieties. We used integrated computational methods to evaluate the potential of the new compounds. Docking experiments demonstrated that two compounds, TAN1 and TAN6, had a strong affinity for the PARP1 active site (- 11.8 and - 10.9 kcal/mol). The ADME/T analysis predicts their improved solubility and bioavailability. In addition, molecular dynamics and MM/PBSA simulations report TAN1 with lower RMSD/RMSF and interact with the ART site, whereas TAN6 shows higher binding free energy (-45.06 kcal/mol) compared to TAN1 (-41.61 kcal/mol) and is close to olaparib (-45.64 kcal/mol) and interacts with HD and the ART site. These differences reflect distinct aspects of protein-ligand interaction and stability. Suggesting that TAN1 and TAN6 are compounds that can interact with PARP1; further replication and experimental validation would be necessary to confirm these findings quantitatively.
Insights
New Tanshinone I derivatives, TAN1 and TAN6, show promise as PARP1 inhibitors for BRCA-driven cancers. Computational studies indicate strong binding affinity and improved properties, suggesting potential for overcoming current treatment limitations.
Area of Science:
- Medicinal Chemistry
- Computational Biology
- Oncology
Background:
- BRCA-driven cancers pose a significant global health challenge.
- Poly(ADP-ribose) polymerase 1 (PARP1) is crucial for DNA repair and cancer cell survival, making it a key therapeutic target.
- Existing PARP1 inhibitors face issues with toxicity and drug resistance, necessitating novel therapeutic scaffolds.
Purpose of the Study:
- To design and computationally evaluate novel Tanshinone I derivatives with improved solubility and bioavailability for targeting PARP1 in BRCA-related cancers.
- To investigate the binding interactions of these derivatives with the PARP1 active site.
Main Methods:
- Chemical modification of Tanshinone I by introducing carboxamide and pyrrolidine moieties.
- Integrated computational approaches including molecular docking, ADME/T analysis, molecular dynamics, and MM/PBSA simulations.
- Evaluation of binding affinity, stability, and interaction sites with PARP1.
Main Results:
- Two derivatives, TAN1 and TAN6, exhibited strong binding affinity to the PARP1 active site.
- ADME/T predictions indicated enhanced solubility and bioavailability for the modified compounds.
- Molecular dynamics and MM/PBSA simulations revealed distinct binding modes and stability profiles for TAN1 and TAN6, with TAN6 showing binding energy comparable to olaparib.
Conclusions:
- TAN1 and TAN6 represent promising novel compounds with the potential to interact effectively with PARP1.
- These derivatives may offer a viable strategy to address limitations of current PARP1 inhibitors in treating BRCA-driven cancers.
- Further experimental validation is required to confirm the therapeutic potential of TAN1 and TAN6.
